Avantax Advisory Services Inc. Has $501,000 Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Avantax Advisory Services Inc. cut its stake in shares of Edwards Lifesciences Co. (NYSE:EWGet Rating) by 9.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,060 shares of the medical research company’s stock after selling 600 shares during the period. Avantax Advisory Services Inc.’s holdings in Edwards Lifesciences were worth $501,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Steel Peak Wealth Management LLC boosted its stake in shares of Edwards Lifesciences by 3.4% in the 2nd quarter. Steel Peak Wealth Management LLC now owns 3,074 shares of the medical research company’s stock worth $292,000 after buying an additional 100 shares during the last quarter. Sheaff Brock Investment Advisors LLC boosted its stake in shares of Edwards Lifesciences by 1.1% in the 2nd quarter. Sheaff Brock Investment Advisors LLC now owns 9,229 shares of the medical research company’s stock worth $878,000 after buying an additional 100 shares during the last quarter. Jeppson Wealth Management LLC boosted its stake in shares of Edwards Lifesciences by 4.3% in the 2nd quarter. Jeppson Wealth Management LLC now owns 2,442 shares of the medical research company’s stock worth $232,000 after buying an additional 100 shares during the last quarter. Comprehensive Financial Consultants Institutional Inc. boosted its stake in shares of Edwards Lifesciences by 1.0% in the 2nd quarter. Comprehensive Financial Consultants Institutional Inc. now owns 10,364 shares of the medical research company’s stock worth $998,000 after buying an additional 104 shares during the last quarter. Finally, Magnus Financial Group LLC boosted its stake in shares of Edwards Lifesciences by 3.9% in the 2nd quarter. Magnus Financial Group LLC now owns 2,866 shares of the medical research company’s stock worth $273,000 after buying an additional 108 shares during the last quarter. 80.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on EW. Canaccord Genuity Group dropped their price objective on Edwards Lifesciences from $78.00 to $73.00 and set a “hold” rating on the stock in a research note on Monday, December 12th. StockNews.com downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday. Mizuho dropped their price objective on Edwards Lifesciences from $100.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, December 7th. Cowen lowered their target price on shares of Edwards Lifesciences from $125.00 to $100.00 in a report on Friday, October 28th. Finally, Raymond James lowered their target price on shares of Edwards Lifesciences from $85.00 to $83.00 and set an “outperform” rating on the stock in a report on Tuesday, December 13th. Eight analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $98.14.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $80.06 on Tuesday. The company has a current ratio of 3.83, a quick ratio of 3.00 and a debt-to-equity ratio of 0.10. The firm has a 50-day moving average of $75.52 and a 200-day moving average of $85.20. The firm has a market cap of $49.50 billion, a P/E ratio of 34.51, a P/E/G ratio of 2.75 and a beta of 1.03. Edwards Lifesciences Co. has a 1-year low of $67.13 and a 1-year high of $131.10.

Edwards Lifesciences (NYSE:EWGet Rating) last posted its earnings results on Thursday, October 27th. The medical research company reported $0.61 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.01). The firm had revenue of $1.32 billion for the quarter, compared to analysts’ expectations of $1.34 billion. Edwards Lifesciences had a return on equity of 24.75% and a net margin of 27.20%. Sell-side analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daveen Chopra sold 4,000 shares of the firm’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $74.18, for a total value of $296,720.00. Following the completion of the sale, the vice president now directly owns 18,911 shares in the company, valued at $1,402,817.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Edwards Lifesciences news, VP Daveen Chopra sold 4,000 shares of the firm’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $74.18, for a total value of $296,720.00. Following the completion of the sale, the vice president now directly owns 18,911 shares in the company, valued at $1,402,817.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 6,725 shares of the firm’s stock in a transaction that occurred on Tuesday, November 8th. The shares were sold at an average price of $68.46, for a total transaction of $460,393.50. Following the transaction, the vice president now directly owns 62,561 shares of the company’s stock, valued at approximately $4,282,926.06. The disclosure for this sale can be found here. Insiders sold 91,800 shares of company stock worth $6,933,324 over the last three months. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

See Also

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.